List of Excipients in Branded Drug HYFTOR

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Nobelpharma America LLC	HYFTOR	sirolimus	73683-101	ALCOHOL
Nobelpharma America LLC	HYFTOR	sirolimus	73683-101	CARBOMER HOMOPOLYMER TYPE C
Nobelpharma America LLC	HYFTOR	sirolimus	73683-101	TROLAMINE
Nobelpharma America LLC	HYFTOR	sirolimus	73683-101	WATER

HYFTOR Excipient Strategy and Commercial Opportunities in Topical Sirolimus

Last updated: September 24, 2026

HYFTOR is a 0.2% sirolimus topical gel approved by the FDA for the topical treatment of facial angiofibroma associated with tuberous sclerosis complex in adults and pediatric patients aged 6 years and older. Its commercial position is supported by orphan-disease status, limited approved competition, and a formulation that converts sirolimus into a self-administered topical product. The main excipient opportunities are improved tolerability, reduced alcohol exposure, better pediatric handling, more precise dosing, and differentiated packaging.

The strongest commercial opportunities are likely to come from lifecycle products rather than a simple excipient substitution. A lower-irritancy gel, alcohol-free or low-alcohol vehicle, metered-dose applicator, and products tailored for younger children or sensitive facial skin could support premium pricing and follow-on exclusivity.

What is HYFTOR and how does its formulation work?

HYFTOR contains sirolimus at a concentration of 0.2%, equivalent to 2 mg/g of gel. Sirolimus is an mTOR inhibitor that suppresses signaling involved in the growth of facial angiofibromas associated with tuberous sclerosis complex.

The product is a topical gel intended for application to affected facial lesions. The formulation is designed to deliver sirolimus locally while limiting the systemic exposure associated with oral sirolimus therapy.

HYFTOR formulation profile

Attribute	HYFTOR profile
Active ingredient	Sirolimus
Strength	0.2%
Dosage form	Topical gel
FDA indication	Facial angiofibroma associated with tuberous sclerosis complex
Approved population	Adults and pediatric patients 6 years and older
Sponsor	Nobelpharma America, LLC
FDA approval	May 2022
Route	Topical
Primary commercial use	Chronic facial lesion management
Regulatory category	Prescription drug; orphan-disease product

The FDA label identifies inactive ingredients that include carbomer 980, ethanol, propylene glycol, purified water, and tromethamine. These materials create a hydroalcoholic gel system with a polymeric thickener, humectant or cosolvent functions, aqueous phase, and pH adjustment.[1]

What excipients are used in HYFTOR?

HYFTOR’s excipient system performs four commercial and technical functions:

1. It solubilizes or disperses sirolimus in a topical vehicle.
2. It creates a gel with sufficient residence time on facial skin.
3. It supports spreadability over multiple small lesions.
4. It maintains product stability during storage and repeated use.

Functional role of the key excipients

Excipient	Likely formulation role	Commercial implication
Carbomer 980	Gel formation, viscosity, residence time	Controls feel, spreadability, and drug release
Ethanol	Solvent and penetration-supporting vehicle	May improve solubility but can cause stinging or dryness
Propylene glycol	Cosolvent, humectant, penetration modifier	Supports solubilization and skin hydration
Purified water	Continuous aqueous phase	Influences viscosity, stability, and drying time
Tromethamine	pH adjustment and buffering	Helps maintain formulation performance and skin compatibility

The formulation is commercially rational for a poorly water-soluble macrolide such as sirolimus. Ethanol and propylene glycol can help maintain the drug in a usable topical system, while carbomer 980 provides the viscosity required for facial application.

The same excipients create potential points of differentiation. Ethanol can produce transient burning, especially on irritated or excoriated skin. Propylene glycol can also cause irritation or contact sensitization in susceptible users. Carbomer concentration affects tackiness, drying time, residue, and drug release.

What excipient strategy could improve HYFTOR?

The most valuable strategy is to preserve sirolimus delivery while reducing the sensory and tolerability disadvantages of a hydroalcoholic gel.

1. Alcohol-free or low-alcohol formulations

An alcohol-free formulation could target patients who experience stinging, dryness, or poor cosmetic acceptance. Candidate systems include:

• Solubilized lipid or microemulsion vehicles
• Nonionic surfactant systems
• Polymeric micelles
• Self-emulsifying drug delivery systems
• Silicone-compatible topical gels
• Water-dispersible nanocrystal systems

The principal technical problem is maintaining sirolimus solubility without increasing crystallization during storage. A lower-alcohol formulation would require robust control of particle size, polymorphic form, supersaturation, and drug release.

An alcohol-free product could have commercial value even if it did not demonstrate superior lesion efficacy. Improved tolerability and cosmetic acceptability can support adherence in a chronic pediatric and adolescent population.

2. Reduced-irritancy solvent systems

A less ambitious program could reduce, rather than eliminate, ethanol. A modified ratio of ethanol, propylene glycol, water, and alternative cosolvents may lower stinging while retaining manufacturing simplicity.

Potential cosolvents include polyethylene glycol derivatives, diethylene glycol monoethyl ether, glycerol derivatives, and selected glycols. Each candidate would require evaluation for:

• Skin irritation and sensitization
• Pediatric exposure
• Residual solvent control
• Drug crystallization
• Permeation into lesional and nonlesional skin
• Compatibility with the gel polymer
• Packaging extractables and leachables

A low-alcohol formulation may provide a more practical regulatory path than a completely new delivery technology.

3. Improved gel rheology

Carbomer 980 is effective but may not provide optimal cosmetic performance for all users. A reformulated gel could target:

• Lower tack
• Faster drying
• Less visible residue
• Easier application around the nose and eyelids
• Better adhesion to uneven lesions
• Reduced runoff during application
• Improved performance under sunscreen or cosmetics

Potential polymer systems include hydroxypropyl cellulose, hydroxyethyl cellulose, poloxamers, acrylates copolymers, and crosslinked polyacrylic acid systems.

The key development risk is that changes in viscosity can alter sirolimus release and skin penetration. A formulation with materially different rheology may require comparative clinical or pharmacokinetic evidence rather than relying solely on pharmaceutical equivalence.

4. Pediatric-friendly delivery

HYFTOR is used in a population that includes children aged 6 years and older. Pediatric usability is therefore a direct commercial opportunity.

Potential improvements include:

• Metered-dose pumps
• Airless dispensers
• Unit-dose sachets
• Narrow-tip applicators
• Controlled-dose tubes
• Packaging that limits contamination from repeated finger contact

A metered package could address under-application and reduce waste. It could also support a defined amount per actuation, improving consistency across lesions.

Packaging may become part of the competitive moat if the delivery system improves dose accuracy without changing the drug formulation. Device claims, human-factors data, and combination-product considerations could create additional intellectual-property positions.

5. Preservative and microbiological strategy

A multidose topical product must control microbial risk. HYFTOR’s ethanol content may contribute to antimicrobial robustness, but a reformulation with less ethanol would require a stronger preservation and packaging strategy.

Commercially attractive options include:

• Preservative-free unit-dose packaging
• Low-bioburden manufacturing
• Airless containers
• Reduced-headspace packaging
• Validated antimicrobial preservation systems

A preservative-free product could appeal to patients with sensitive skin, but it may have higher packaging costs and more demanding manufacturing controls.

What patents protect HYFTOR and its formulation?

HYFTOR’s commercial protection is likely to rely on a combination of:

• Sirolimus topical composition claims
• Gel vehicle and excipient claims
• Concentration and dosage claims
• Methods for treating facial angiofibroma
• Packaging or delivery-system claims
• Manufacturing and stability claims

The core composition and method-of-use claims are more important than any individual excipient. A generic or follow-on sponsor would need to assess whether its formulation falls within listed composition claims, whether it can use the same indication, and whether non-listed method-of-use patents affect labeling.

Orange Book and exclusivity position

HYFTOR was approved through the FDA’s standard new-drug pathway and received orphan-drug designation for the treatment of facial angiofibroma associated with tuberous sclerosis complex. Orphan-drug exclusivity generally provides seven years of protection from approval for the designated indication under the Orphan Drug Act.[2]

The expected orphan-exclusivity window runs into 2029, subject to the precise designation and approval dates recorded by FDA. Patent expiration may extend beyond regulatory exclusivity. The practical entry date depends on the later of applicable regulatory restrictions, enforceable patents, and any litigation-related stay.

FDA Orange Book records, rather than commercial patent databases, control the operative list of patents submitted for HYFTOR. Patent scope should be evaluated claim by claim. A patent covering a topical sirolimus gel may create greater entry risk than a narrow method claim limited to a particular lesion or dosing schedule.

When does HYFTOR lose exclusivity?

HYFTOR’s exclusivity has several layers:

Protection layer	Commercial effect
Orphan-drug exclusivity	Blocks FDA approval of the same drug for the same orphan indication during the exclusivity period, subject to statutory exceptions
Listed patents	May delay an ANDA applicant or require a Paragraph IV certification
Method-of-use claims	Can restrict labeling for the protected indication or regimen
Formulation claims	May require a non-infringing vehicle or a different development pathway
Regulatory data package	Supports approval strategy and raises development costs for follow-on products
Trademark and trade dress	Protects branding but does not prevent therapeutic substitution

Orphan exclusivity does not prevent all competing products. A different drug, a different strength, or a product for a different indication may avoid the exclusivity block. Compounding, off-label use, and physician-directed alternatives also are not necessarily eliminated by orphan protection.

Are there Paragraph IV challenges to HYFTOR?

A Paragraph IV challenge would require an ANDA applicant to certify that one or more Orange Book-listed patents are invalid, unenforceable, or not infringed. The applicant would typically notify the patent holder, potentially triggering patent litigation and a 30-month FDA approval stay under the Hatch-Waxman framework.[3]

HYFTOR’s commercial profile reduces the immediate incentive for an ANDA challenge compared with a high-volume chronic medicine. The indication is narrow, the market is specialist-driven, and pediatric topical formulation complexity may limit expected generic volume.

The risk can increase if:

• Annual treatment cost is high
• Use expands beyond the original orphan population
• Several generic manufacturers pursue the same topical vehicle
• A court narrows the formulation patent estate
• Orphan exclusivity expires before major patent barriers
• A non-infringing formulation can be approved through an ANDA

A first Paragraph IV filer could seek 180-day exclusivity if it satisfies the statutory requirements. That incentive is meaningful only if the expected market supports litigation and commercial launch costs.

What generic entry risks exist for HYFTOR?

Generic entry risks fall into four categories.

Same-formulation generic

A generic manufacturer may attempt to replicate the 0.2% sirolimus gel. This route would face the greatest patent and formulation-equivalence exposure but could offer the clearest FDA pathway if pharmaceutical equivalence and bioequivalence requirements can be met.

Non-infringing topical formulation

A sponsor could develop a different gel, cream, foam, ointment, or emulsion. This strategy may avoid composition claims but could require clinical evidence because topical bioequivalence standards can be complex.

Compounded sirolimus

Compounding may provide local alternatives, particularly through specialty pharmacies. Compounded products do not generally provide the same FDA-approved labeling, manufacturing controls, or commercial scale as HYFTOR, but they can pressure pricing in small patient populations.

Alternative mTOR products

Oral sirolimus and other mTOR-directed therapies may be used in selected patients, but they have different systemic exposure and safety considerations. They are not direct generic substitutes for a localized topical product.

How does HYFTOR compare with competing treatments?

Treatment	Route	Main use in TSC-related angiofibroma	Commercial position
HYFTOR	Topical sirolimus gel	Facial angiofibroma	FDA-approved topical drug with orphan protection
Oral sirolimus	Systemic	Severe or multisystem TSC manifestations	Greater systemic exposure; not a direct topical substitute
Everolimus	Systemic	Selected TSC-associated tumors and seizures	Different safety and reimbursement profile
Laser therapy	Procedural	Lesion reduction	Immediate cosmetic effect but recurrence and procedure burden
Electrosurgery or dermabrasion	Procedural	Lesion removal or reduction	Operator-dependent and less convenient for widespread lesions
Compounded topical sirolimus	Topical	Off-label or individualized treatment	Lower regulatory certainty and variable formulation quality

HYFTOR’s commercial advantage is the combination of an FDA-approved topical route and chronic-use suitability. Procedural treatments may remain important for patients requiring rapid cosmetic improvement or treatment of larger lesions.

What licensing and partnering opportunities exist?

The most plausible licensing opportunities are formulation and delivery collaborations rather than acquisition of the active ingredient.

High-value partnership areas

• Alcohol-free sirolimus gel technology
• Nanocrystal or micellar delivery systems
• Pediatric metered-dose packaging
• Preservative-free multidose systems
• Manufacturing of sterile or low-bioburden topical products
• Regional commercialization rights
• Dermatology specialty-pharmacy distribution
• Digital adherence and refill programs

A partner with proprietary solubilization technology could offer a differentiated product without changing sirolimus pharmacology. A packaging company could contribute device intellectual property and manufacturing scale.

Licensing value would depend on whether the technology supports a 505(b)(2) product, an improved formulation with clinical differentiation, or an ANDA-compatible generic. A formulation that requires a new clinical program has a higher development burden but may provide stronger exclusivity.

What is the commercial opportunity for HYFTOR lifecycle products?

The patient population is small but concentrated in specialty care. Tuberous sclerosis complex affects approximately 1 in 6,000 live births, and facial angiofibromas occur in a substantial share of affected patients.[4] The commercial opportunity depends less on broad primary-care penetration than on diagnosis, treatment persistence, reimbursement, and use across pediatric and adult patients.

Priority product concepts

Product concept	Patient benefit	Likely regulatory burden	Commercial potential
Low-alcohol gel	Less stinging and dryness	Moderate	High
Alcohol-free emulsion or gel	Better tolerability and cosmetic acceptance	High	High
Metered-dose pump	More consistent dosing	Moderate	Moderate to high
Unit-dose sachets	Hygiene and portability	Moderate	Moderate
Faster-drying gel	Better daily-use adherence	Moderate	Moderate
Pediatric applicator	Easier caregiver administration	Moderate	Moderate
Higher-strength formulation	Lower application volume	High	Uncertain
Combination topical therapy	Broader lesion management	High	Potentially high

A higher-strength formulation could reduce application burden but may increase irritation and systemic exposure. A combination product may have greater market potential but would require a clear clinical rationale and additional safety evidence.

How strong is the HYFTOR patent estate?

The estate is commercially stronger when formulation claims, use claims, and orphan exclusivity overlap. It is weaker if protection depends mainly on a narrow indication claim and the formulation can be redesigned without materially affecting delivery.

Strength indicators

• FDA-approved indication with limited direct competition
• Orphan-drug exclusivity
• Specialized topical delivery of a poorly water-soluble drug
• Potential formulation and method-of-use patent layers
• Pediatric and chronic-use positioning
• High switching friction if patients are stable on therapy

Weakness indicators

• Small addressable market
• Potential for compounded alternatives
• Ability to alter excipients or dosage form
• Limited need for systemic bioequivalence if a competitor pursues a new topical product
• Potentially modest commercial value for generic litigation

A competitor’s most defensible strategy would likely be a clinically improved formulation, not a direct copy. A non-infringing alcohol-free product with comparable efficacy could create a separate branded market while avoiding some direct patent exposure.

What FDA regulatory pathway applies to follow-on HYFTOR products?

A direct generic would generally pursue an ANDA if it can demonstrate the required sameness and bioequivalence. A materially different topical vehicle or delivery system may require a 505(b)(2) application.

The pathway depends on the extent of change:

Change	Likely pathway consideration
Same strength, dosage form, and inactive ingredients	ANDA may be viable
Different inactive ingredients but equivalent topical performance	ANDA feasibility depends on FDA requirements
New delivery device	ANDA or 505(b)(2), depending on product differences
Alcohol-free formulation with new vehicle	505(b)(2) is more likely
New strength or dosing regimen	505(b)(2) or full NDA considerations
New indication	Separate clinical and patent analysis required

The main development issue is demonstrating equivalent local performance. Topical sirolimus cannot be evaluated solely through conventional plasma pharmacokinetics because therapeutic activity is localized in skin lesions.

Key Takeaways

• HYFTOR is a 0.2% topical sirolimus gel approved for facial angiofibroma associated with tuberous sclerosis complex.
• Its excipient system uses carbomer 980, ethanol, propylene glycol, purified water, and tromethamine.
• The leading formulation opportunity is a lower-irritancy, low-alcohol or alcohol-free product.
• Pediatric delivery, metered dosing, faster drying, and improved cosmetic feel are commercially relevant differentiators.
• Orphan-drug exclusivity is expected to run into 2029, while patent protection may extend beyond that period.
• Generic risk is limited by the small specialist market but could rise if treatment adoption and pricing expand.
• A non-infringing 505(b)(2) product may be more commercially attractive than a direct ANDA copy.
• The strongest lifecycle strategy combines excipient reformulation with packaging, usability, and method-of-use intellectual property.

FAQs

Can HYFTOR be reformulated without losing its orphan-drug commercial advantage?

Yes. A reformulated product may retain market recognition and clinical positioning, but material changes to the vehicle, strength, or delivery system can require new FDA evidence and may not automatically inherit every protection associated with the original product.

Is an alcohol-free sirolimus gel likely to be commercially differentiated?

Yes. Reduced stinging, less dryness, and improved cosmetic acceptance could support premium positioning, especially for children and patients using the product chronically.

Can a generic manufacturer avoid HYFTOR patents by changing the excipients?

Potentially. A changed excipient system may avoid composition claims, but the sponsor must still address method-of-use claims, equivalence requirements, stability, topical performance, and any listed patents.

Would a metered-dose pump create separate patent value?

It could. A pump that controls delivered sirolimus dose, reduces contamination, or improves pediatric administration may support device, packaging, or combination-product claims.

Is compounded topical sirolimus a major threat to HYFTOR?

It is a localized threat, particularly where reimbursement is weak or patients seek lower-cost alternatives. FDA-approved manufacturing, labeling, consistency, and specialist prescribing support HYFTOR’s advantage over compounded products.

References

1. U.S. Food and Drug Administration. (2022). HYFTOR (sirolimus) topical gel, 0.2%: Prescribing information. Nobelpharma America, LLC.

2. U.S. Food and Drug Administration. (2023). Orphan drug designation and exclusivity. https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services.

4. Northrup, H., Aronow, M. E., Bebin, E. M., et al. (2021). Updated international tuberous sclerosis complex diagnostic criteria and surveillance and management recommendations. Pediatric Neurology, 123, 50-66.